EEG biomarkers of AD have also been linked to other biomarkers including reductions of glucose metabolism in the temporo-parietal regions as measured by FDG PET [45], cortical and hippocampal atrophy measured with structural MRI, decreased levels of beta amyloid, and increased levels of phospho-tau and total tau in the CSF [46]. The gene discussed is MAPT; the disease is Alzheimer disease.